EGFR, SMAD7, and TGFBR2 polymorphisms are associated with colorectal cancer in patients with lynch syndrome

Abram Bunya Kamiza; Wen Chang Wang; Jeng Fu You; Reiping Tang; Yen Ting Wang; Huei Tzu Chien; Chih Hsiung Lai; Li Ling Chiu; Tsai Ping Lo; Kuan Yi Hung; Chao Agnes Hsiung; Chih Ching Yeh

doi:10.21873/anticanres.12946

EGFR, SMAD7, and TGFBR2 polymorphisms are associated with colorectal cancer in patients with lynch syndrome

Abram Bunya Kamiza, Wen Chang Wang, Jeng Fu You, Reiping Tang, Yen Ting Wang, Huei Tzu Chien, Chih Hsiung Lai, Li Ling Chiu, Tsai Ping Lo, Kuan Yi Hung, Chao Agnes Hsiung, Chih Ching Yeh^*

^*Corresponding author for this work

School of Traditional Chinese Medicine

Research output: Contribution to journal › Journal Article › peer-review

5 Scopus citations

Abstract

Background/Aim: Epidermal growth factor receptor (EGFR), mothers against decapentaplegic homolog 7 (SMAD7) and transforming growth factor betta (TGFB) are crucial for colorectal cancer (CRC) tumorigenesis. This study investigated whether polymorphisms in EGFR, SMAD7, and TGFB are associated with CRC risk in patients with Lynch syndrome. Materials and Methods: Genotyping was performed using Sequenom iPLEX MassArray. Association between genetic polymorphisms and CRC was assessed using a weighted Cox proportional hazard model. Results: Patients carrying the AA genotype of EGFR rs2227983 had a significantly higher CRC risk than those carrying the G allele (HR=2.55, 95% CI=1.25-5.17). The dominant model of SMAD7 rs12953717 (CT + TT genotypes) significantly increased CRC risk (HR=2.17, 95% CI=1.12-4.16) when compared to the wild-type CC genotype. Similarly, the GG genotype of TGFBR2 rs6785358 significantly increased the risk of CRC (HR=21.1, 95% CI=5.06-88.1) compared to the AA genotype. Conclusion: EGFR, SMAD7, and TGFBR2 are associated with CRC risk in patients with Lynch syndrome.

Original language	English
Pages (from-to)	5983-5990
Number of pages	8
Journal	Anticancer Research
Volume	38
Issue number	10
DOIs	https://doi.org/10.21873/anticanres.12946
State	Published - 10 2018

Bibliographical note

Publisher Copyright:
© 2018 International Institute of Anticancer Research. All rights reserved.

Keywords

CRC risk
Colorectal cancer
EGFR
Lynch syndrome
Polymorphisms
SMAD7
TGFB

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.21873/anticanres.12946

Cite this

@article{28dce2bf36944a8eb4dc48222b99a828,

title = "EGFR, SMAD7, and TGFBR2 polymorphisms are associated with colorectal cancer in patients with lynch syndrome",

abstract = "Background/Aim: Epidermal growth factor receptor (EGFR), mothers against decapentaplegic homolog 7 (SMAD7) and transforming growth factor betta (TGFB) are crucial for colorectal cancer (CRC) tumorigenesis. This study investigated whether polymorphisms in EGFR, SMAD7, and TGFB are associated with CRC risk in patients with Lynch syndrome. Materials and Methods: Genotyping was performed using Sequenom iPLEX MassArray. Association between genetic polymorphisms and CRC was assessed using a weighted Cox proportional hazard model. Results: Patients carrying the AA genotype of EGFR rs2227983 had a significantly higher CRC risk than those carrying the G allele (HR=2.55, 95% CI=1.25-5.17). The dominant model of SMAD7 rs12953717 (CT + TT genotypes) significantly increased CRC risk (HR=2.17, 95% CI=1.12-4.16) when compared to the wild-type CC genotype. Similarly, the GG genotype of TGFBR2 rs6785358 significantly increased the risk of CRC (HR=21.1, 95% CI=5.06-88.1) compared to the AA genotype. Conclusion: EGFR, SMAD7, and TGFBR2 are associated with CRC risk in patients with Lynch syndrome.",

keywords = "CRC risk, Colorectal cancer, EGFR, Lynch syndrome, Polymorphisms, SMAD7, TGFB",

author = "Kamiza, {Abram Bunya} and Wang, {Wen Chang} and You, {Jeng Fu} and Reiping Tang and Wang, {Yen Ting} and Chien, {Huei Tzu} and Lai, {Chih Hsiung} and Chiu, {Li Ling} and Lo, {Tsai Ping} and Hung, {Kuan Yi} and Hsiung, {Chao Agnes} and Yeh, {Chih Ching}",

year = "2018",

month = oct,

doi = "10.21873/anticanres.12946",

language = "英语",

volume = "38",

pages = "5983--5990",

journal = "Anticancer Research",

issn = "0250-7005",

publisher = "International Institute of Anticancer Research",

number = "10",

}

TY - JOUR

T1 - EGFR, SMAD7, and TGFBR2 polymorphisms are associated with colorectal cancer in patients with lynch syndrome

AU - Kamiza, Abram Bunya

AU - Wang, Wen Chang

AU - You, Jeng Fu

AU - Tang, Reiping

AU - Wang, Yen Ting

AU - Chien, Huei Tzu

AU - Lai, Chih Hsiung

AU - Chiu, Li Ling

AU - Lo, Tsai Ping

AU - Hung, Kuan Yi

AU - Hsiung, Chao Agnes

AU - Yeh, Chih Ching

PY - 2018/10

Y1 - 2018/10

N2 - Background/Aim: Epidermal growth factor receptor (EGFR), mothers against decapentaplegic homolog 7 (SMAD7) and transforming growth factor betta (TGFB) are crucial for colorectal cancer (CRC) tumorigenesis. This study investigated whether polymorphisms in EGFR, SMAD7, and TGFB are associated with CRC risk in patients with Lynch syndrome. Materials and Methods: Genotyping was performed using Sequenom iPLEX MassArray. Association between genetic polymorphisms and CRC was assessed using a weighted Cox proportional hazard model. Results: Patients carrying the AA genotype of EGFR rs2227983 had a significantly higher CRC risk than those carrying the G allele (HR=2.55, 95% CI=1.25-5.17). The dominant model of SMAD7 rs12953717 (CT + TT genotypes) significantly increased CRC risk (HR=2.17, 95% CI=1.12-4.16) when compared to the wild-type CC genotype. Similarly, the GG genotype of TGFBR2 rs6785358 significantly increased the risk of CRC (HR=21.1, 95% CI=5.06-88.1) compared to the AA genotype. Conclusion: EGFR, SMAD7, and TGFBR2 are associated with CRC risk in patients with Lynch syndrome.

AB - Background/Aim: Epidermal growth factor receptor (EGFR), mothers against decapentaplegic homolog 7 (SMAD7) and transforming growth factor betta (TGFB) are crucial for colorectal cancer (CRC) tumorigenesis. This study investigated whether polymorphisms in EGFR, SMAD7, and TGFB are associated with CRC risk in patients with Lynch syndrome. Materials and Methods: Genotyping was performed using Sequenom iPLEX MassArray. Association between genetic polymorphisms and CRC was assessed using a weighted Cox proportional hazard model. Results: Patients carrying the AA genotype of EGFR rs2227983 had a significantly higher CRC risk than those carrying the G allele (HR=2.55, 95% CI=1.25-5.17). The dominant model of SMAD7 rs12953717 (CT + TT genotypes) significantly increased CRC risk (HR=2.17, 95% CI=1.12-4.16) when compared to the wild-type CC genotype. Similarly, the GG genotype of TGFBR2 rs6785358 significantly increased the risk of CRC (HR=21.1, 95% CI=5.06-88.1) compared to the AA genotype. Conclusion: EGFR, SMAD7, and TGFBR2 are associated with CRC risk in patients with Lynch syndrome.

KW - CRC risk

KW - Colorectal cancer

KW - EGFR

KW - Lynch syndrome

KW - Polymorphisms

KW - SMAD7

KW - TGFB

UR - http://www.scopus.com/inward/record.url?scp=85054062384&partnerID=8YFLogxK

U2 - 10.21873/anticanres.12946

DO - 10.21873/anticanres.12946

M3 - 文章

C2 - 30275229

AN - SCOPUS:85054062384

SN - 0250-7005

VL - 38

SP - 5983

EP - 5990

JO - Anticancer Research

JF - Anticancer Research

IS - 10

ER -

EGFR, SMAD7, and TGFBR2 polymorphisms are associated with colorectal cancer in patients with lynch syndrome

Abstract

Bibliographical note

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this